STOCK TITAN

Microbot Medical Inc. - $MBOT STOCK NEWS

Welcome to our dedicated page for Microbot Medical news (Ticker: $MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Medical stock.

Microbot Medical, Inc. (NASDAQ: MBOT) is a pioneering pre-clinical medical device company focused on developing groundbreaking micro-robotic medical technologies. Established with the vision to transform minimally invasive surgeries—a fast-growing sector estimated to be close to $20 billion by 2015—Microbot Medical aims to provide cutting-edge micro-invasive technologies that assist physicians in targeting disease sites with unmatched precision. The company's innovative platforms, such as LIBERTY and the Self-Cleaning Shunt (SCS), are designed to improve surgical outcomes and the quality of life for millions of patients globally.

One of Microbot Medical's core technologies, the Virob platform, is an autonomous advancing micro-robot (AAMR) less than 1mm in diameter. This micro-robot can advance forward and backward autonomously, providing precise navigation through the body. Similarly, the LIBERTY Endovascular Robotic Surgical System aims to revolutionize endovascular procedures by eliminating the need for bulky and expensive equipment while reducing radiation exposure and physician strain.

Microbot Medical has been achieving significant milestones, including positive results from its pivotal GLP pre-clinical study and its recent Investigational Device Exemption (IDE) application to the FDA. These advancements pave the way for the company's first human clinical trials. Furthermore, the company has secured both domestic and global patents, fortifying its product portfolio and creating significant barriers to entry for competitors.

Microbot Medical is actively engaging in pre-commercial activities and strategic partnerships to ensure efficient commercialization channels for the LIBERTY system once it receives regulatory approval. The company is committed to advancing its technologies and aims to integrate future capabilities such as remote operations, imaging integration, and AI functionalities.

Despite challenges such as the COVID-19 pandemic and recent geopolitical events in Israel, Microbot Medical continues to meet its planned timelines and milestones. The company’s operations in Israel, the USA, and other parts of the globe remain uninterrupted, and it believes it will achieve regulatory and commercial milestones as scheduled.

For further information about Microbot Medical, please visit www.microbotmedical.com.

Rhea-AI Summary

Microbot Medical has partnered with Brigham and Women's Hospital (BWH) to conduct a pivotal human clinical trial for its LIBERTY® Endovascular Robotic Surgical System. This follows the FDA's approval to commence the trial. BWH has received multiple LIBERTY systems and completed the Site Initiation Visit, which included training for clinical staff. Dr. Dmitry Rabkin will lead the study at BWH. Microbot is also engaging other leading centers to participate in the trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership clinical trial
-
Rhea-AI Summary

Microbot Medical has announced that Brigham and Women’s Hospital (BWH) in Boston will be a site for its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System as part of its Investigational Device Exemption (IDE) application. Dr. Dmitry Rabkin has been appointed as the principal investigator at BWH. The site initiation visit has been completed, and BWH staff have been trained on the clinical study protocols. Additionally, a shipment of LIBERTY investigational units has been delivered to BWH. Microbot Medical is also in the process of enlisting other leading centers for the clinical trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
-
Rhea-AI Summary

Microbot Medical (NASDAQ: MBOT) announced the closing of a $2.35 million registered direct offering priced at-the-market under Nasdaq rules, selling 1,566,669 shares at $1.50 per share. Concurrently, the company issued unregistered Series F preferred investment options for up to 3,133,338 shares at $1.50 per share, exercisable for two years. H.C. Wainwright & Co. acted as the exclusive placement agent. The company plans to use the net proceeds for the development and commercialization of the LIBERTY® Robotic System, expansion of its IP portfolio, and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) has announced a registered direct offering for the purchase and sale of 1,566,669 shares at $1.50 per share, totaling approximately $2.35 million in gross proceeds. Concurrently, unregistered series F preferred investment options to purchase up to 3,133,338 shares at the same price will be issued in a private placement. The closing is expected around June 4, 2024, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. The net proceeds will fund the development and commercialization of the LIBERTY® Robotic System, other IP projects, and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38%
Tags
-
Rhea-AI Summary

Microbot Medical has received FDA approval to start its pivotal human clinical trial for the LIBERTY® Endovascular Robotic Surgical System.

The trial will be conducted in the U.S. and will complement preclinical data to support a future 510(k) submission. The company has signed a clinical trial service agreement with a leading academic medical center and is engaging additional centers.

In parallel, Microbot Medical is completing biocompatibility tests required for the IDE application. CEO Harel Gadot expressed confidence in the technology and commitment to achieving regulatory clearance and commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38%
Tags
-
Rhea-AI Summary

Microbot Medical Inc. (Nasdaq: MBOT) has announced the successful completion of the first phase of its collaboration with Corewell Health, showcasing the technical capabilities of its LIBERTY® Endovascular Robotic Surgical System. The partnership aims to explore remote endovascular procedures utilizing the LIBERTY System. Led by Dr. Ryan Madder, the collaboration has shown promising results in a pre-clinical study published in the Journal of the American College of Cardiology: Cardiovascular Interventions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.84%
Tags
none
Rhea-AI Summary
Microbot Medical Inc. (MBOT) remains resilient amidst recent geopolitical events in Israel, with all regulatory, clinical, operational, and pre-commercial activities progressing as planned. The company is confident in achieving regulatory and commercial milestones on schedule, including FDA IDE submission, ISO 13485 certification audits, and partnerships for future capabilities of the LIBERTY® Endovascular Robotic Surgical System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
none
-
Rhea-AI Summary
Microbot Medical Inc. (MBOT) has filed an Investigational Device Exemption (IDE) application with the US Food and Drug Administration (FDA) for its LIBERTY® Endovascular Robotic Surgical System. The approval of the IDE application would allow the company to commence its pivotal human clinical trial in the United States. This marks an important milestone for the company in its journey to achieve FDA clearance for the surgical system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
-
Rhea-AI Summary
Microbot Medical Inc. (MBOT) has signed a Settlement Agreement and Release with several entities, resolving all claims asserted against the Company in a lawsuit filed in 2020. The settlement amount, over half of which will be covered by Microbot's insurance carrier, will not impact the company's cash position or balance sheet. CEO Harel Gadot believes that resolving this matter while maintaining the company's cash position is in the best interest of shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) announces the addition of a US-based Clinical Research Associate (CRA) to support its anticipated IDE submission for its first in human clinical trial following positive results of its pivotal GLP pre-clinical study. The CRA will join the established clinical team in the USA, led by Dr. Juan Diaz-Cartelle, the Company’s Chief Medical Officer. This move aims to establish the right infrastructure for clinical trial execution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.35%
Tags

FAQ

What is Microbot Medical, Inc.?

Microbot Medical, Inc. is a pre-clinical medical device company specializing in developing next-generation micro-robotic medical technologies for minimally invasive procedures.

What is the LIBERTY Endovascular Robotic Surgical System?

The LIBERTY Endovascular Robotic Surgical System is an innovative platform aimed at improving endovascular procedures by eliminating the need for large, cumbersome equipment while reducing radiation exposure and physician strain.

What recent achievements has Microbot Medical accomplished?

Microbot Medical recently achieved positive results from its pivotal GLP pre-clinical study and submitted an IDE application to the FDA, paving the way for its first human clinical trials.

What are the core technologies developed by Microbot Medical?

Microbot Medical's core technologies include the Virob platform, an autonomous advancing micro-robot, and the LIBERTY Endovascular Robotic Surgical System.

What is the vision of Microbot Medical?

Microbot Medical aims to transform minimally invasive surgeries by providing cutting-edge micro-invasive technologies that help physicians target disease sites with unmatched precision.

How is Microbot Medical preparing for commercialization?

Microbot Medical is engaging in pre-commercial activities and strategic partnerships to ensure efficient commercialization channels for its technologies once regulatory approvals are obtained.

What impact do recent geopolitical events have on Microbot Medical's operations?

Despite recent geopolitical events in Israel, Microbot Medical's operations in Israel, the USA, and other parts of the globe remain uninterrupted, and the company believes it will achieve its regulatory and commercial milestones as scheduled.

What is the Self-Cleaning Shunt (SCS) developed by Microbot Medical?

The Self-Cleaning Shunt (SCS) is another innovative platform developed by Microbot Medical aimed at improving the quality of life for patients by providing less invasive and more precise solutions for surgical procedures.

Who is acting as the exclusive placement agent for Microbot Medical's offering?

H.C. Wainwright & Co. is acting as the exclusive placement agent for Microbot Medical's offering.

How can I get more information about Microbot Medical?

For more information about Microbot Medical, you can visit their website at www.microbotmedical.com.

Microbot Medical Inc.

Nasdaq:MBOT

MBOT Rankings

MBOT Stock Data

16.60M
14.17M
1.52%
10.55%
2.12%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
HINGHAM